AzTrials
AzTrials

Stroke, IschemicNCT05623943

Comparison of Cerebral Artery Pressure Gradient and Cerebral Blood Flow Measured by Arterial Spin Labeling

An observational study of Stroke, Ischemic and Intracranial Atherosclerosis, run by Xuanwu Hospital, Beijing at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this observational study is to explore the ability of intravascular pressure gradients to identify hemodynamic disturbance in patients with intracranial atherosclerotic diseases (ICAS). Read more about this study

Who is it for?
Ages 40 years and older
What is being tested?
Endovascular treatment
Type of treatment
Surgery or procedure
How many people
25 participants
Where
1 siteChina
Study dates
1 Jun 2019to 1 Feb 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with symptomatic ICAS resorting to endovascular therapy in our center were recruited consecutively.

Who may be able to join

  • Patients aged 40 years or older.
  • Patients with transient ischemic attack (TIA) or nondisabling ischemic stroke caused by a focal ICAS lesion located in intracranial anterior circulation (vertebral artery, basilar artery or intracranial internal carotid artery and their major branches).
  • 50% to 99% stenosis (calculated by modified WASID method) of responsible arterial occlusion, confirmed by digital subtraction angiography (DSA).
  • Informed of the study protocol and objectives.

Who cannot join

  • Non-atherosclerotic MCA stenosis
  • Combined with moderate or severe stenosis of other extracranial and intracranial arteries
  • Previous endovascular treatment or surgery for cerebrovascular diseases
  • Large cerebral infarction (more than 1/2 MCA perfusion area)
  • Combined with other neurological diseases, such as aneurysm, arteriovenous malformation, tumor, hydrocephalus, cerebral trauma, cerebral hemorrhage, multiple sclerosis, epilepsy and intracranial infection.
  • Vascular abnormality or stunting, resulting in the impossibility of endovascular intervention
Show all 11Show fewer
  • Liver and kidney dysfunction, or severe allergy to the contrast agent
  • Severe coagulation dysfunction
  • Pregnancy or in the preparation for pregnancy
  • Patients who cannot tolerate or do not allow MR screening, including metal implanting and claustrophobia
  • Patients with severe dementia or mental disorders, who cannot cooperate with examination

Trial locations and contacts

1 site in 1 country.

China1 site
  • Xuanwu Hospital, Capital Medical University

    Beijing, Beijing Municipality

Other trials in China

About this study

The goal of this observational study is to explore the ability of intravascular pressure gradients to identify hemodynamic disturbance in patients with intracranial atherosclerotic diseases (ICAS). The main questions that aim to answer are:

  • The correlation between intravascular pressure gradient and cerebral blood flow (CBF)
  • The threshold for intravascular pressure gradients to predict hemodynamic disturbance in ICAS

Patients will undergo intravascular pressure measurement and arterial spin labeling (ASL) for CBF during pre- and post-operation respectively.

Being tested
Endovascular treatment
Keywords
Intracranial atherosclerotic diseases, Fractional Flow Reserve, intravascular pressure gradients, Cerebral blood flow, Arterial Spin Labeling
Medical subject headings
Ischemic Stroke, Intracranial Arteriosclerosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Endovascular treatmentProcedure or surgery

    Patients treated with endovascular treatment, including balloon angioplasty alone and balloon angioplasty plus stenting.

Study groups in NCT05623943
Study groupRoleWhat they receive
ICAS patients planning for endovascular treatmentPatients received pressure-wire-based intravascular pressure measurement and ASL measurement before and after operation.
Receives: Procedure: Endovascular treatment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The relevance between intravascular pressure gradients and CBF

    Patients will be divided into 2 groups according to whether they have hemodynamic disorders before operation and improve after operation. Fractional flow reserve (FFR) measurement will be analyzed in each group.

    Measured: Post-operation, an average of 3 days

Secondary outcomes (4)
  1. The difference of ASL-CBF between pre- and post-operation

    The mean cerebral blood flow (CBF) of ipsilateral region of interest (ROI) in two different layers will be recorded as CBF in MCA perfusion area of this side. Relative CBF (rCBF) is defined as the ratio of the affected side CBF to the contralateral CBF. When preoperative rCBF<0.9 and postoperative rCBF≥0.9, the patient will be considered to have hemodynamic disorders and be improved post-operation.

    Measured: Baseline and Post-operation, an average of 3 days

  2. The difference of FFR between pre- and post-operation

    FFR measurement will be performed at rest by 0.014-inch pressure guide wires (C12008, Abbot St. Jude Medical, Minneapolis, MN, USA) designed for coronary diseases. The mean endovascular pressure of distal and proximal lesions will be measured and recorded as Pd and Pa, respectively. Pd/Pa and Pa-Pd will be calculated and recorded before and after endovascular treatment.

    Measured: Baseline and Post-operation, an average of 3 days

  3. Any stroke or death in short term.

    Measured: 30±5 days

  4. Procedure-related complications

    Any complications, related to manometry and treatment, will be recorded including arterial dissection, arterial perforation, acute vascular occlusion and other adverse events.

    Measured: 30±5 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Nov 2022
  2. Study start1 Jun 2019
  3. Primary completion1 Jan 2023
  4. Study completion1 Feb 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
25 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05623943
Sponsor's protocol ID
XWFFR-1
Status last verified
Nov 2022
First submitted
28 Oct 2022
Last updated
27 Apr 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Stroke, Ischemic and Intracranial Atherosclerosis, run by Xuanwu Hospital, Beijing at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The relevance between intravascular pressure gradients and CBF (time frame: Post-operation, an average of 3 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in